Gadofluorine m-enhanced magnetic resonance imaging of inflammatory bowel disease: Quantitative analysis and histologic correlation in a rat model

Investigative Radiology

Volumn 46, Issue 8, 2011, Pages 478-485

  Frericks, Bernd B ^a   Kühl, Anja A ^a   Loddenkemper, Christoph ^a   Stroux, Andrea ^a   Valdeig, Steffi ^b   Hotz, Birgit ^a   Misselwitz, Bernd ^c   Hoffmann, Jörg C ^d   Wacker, Frank K ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYER PHARMA AG   (Germany)

^d St Marienkrankenhaus   (Germany)

Author keywords

colitis; contrast media; histology comparative studies; inflammatory bowel disease; magnetic resonance imaging

Indexed keywords

GADOFLUORINE M; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENTERITIS; HISTOPATHOLOGY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

EID: 79959800239     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31821459ff     Document Type: Article

References (42)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. (Pubitemid 46722637)
2. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(suppl 1):i16-i35. (Pubitemid 43268291)
3. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231-235. (Pubitemid 24092870)
4. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670-1689. (Pubitemid 350029755)
5. Gore RM, Balthazar EJ, Ghahremani GG, et al. CT features of ulcerative colitis and Crohn's disease. Am J Roentgenol. 1996;167:3-15. (Pubitemid 26196899)
6. Jorgensen LG, Fredholm L, Hyltoft Petersen P, et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? Clin Chem Lab Med. 2005;43:403-411. (Pubitemid 41460647)
7. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100-1105. (Pubitemid 47402593)
8. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut. 2009;58:859-868.
9. Svensson MH, Svensson E, Lasson A, et al. Patient acceptance of CT colonography and conventional colonoscopy: prospective comparative study in patients with or suspected of having colorectal disease. Radiology. 2002; 222:337-345. (Pubitemid 34106101)
10. Albert JG, Martiny F, Krummenerl A, et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut. 2005;54:1721-1727. (Pubitemid 41697670)
11. Golder SK, Schreyer AG, Endlicher E, et al. Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. Int J Colorectal Dis. 2006;21:97-104. (Pubitemid 43154428)
12. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68:255-266. (Pubitemid 352024383)
13. Wold PB, Fletcher JG, Johnson CD, et al. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy-feasibility study. Radiology. 2003;229:275-281. (Pubitemid 37152136)
14. Louis E, Ancion G, Colard A, et al. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 2007;48: 1053-1059. (Pubitemid 47052642)
15. Desmond AN, O'Regan K, Curran C, et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut. 2008;57:1524-1529.
16. Schreyer AG, Seitz J, Feuerbach S, et al. Modern imaging using computer tomography and magnetic resonance imaging for inflammatory bowel disease (IBD) AU1. Inflamm Bowel Dis. 2004;10:45-54. (Pubitemid 38072446)
17. Maccioni F, Bruni A, Viscido A, et al. MR imaging in patients with Crohn disease: value of T2-versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology. 2006;238:517-530. (Pubitemid 43134364)
18. Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel followthrough as diagnostic techniques. Radiology. 2009;251:751-761.
19. Ajaj WM, Lauenstein TC, Pelster G, et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut. 2005;54:257-263. (Pubitemid 40139243)
20. Schreyer AG, Rath HC, Kikinis R, et al. Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study. Gut. 2005;54:250-256. (Pubitemid 40139242)
21. Florie J, Wasser MN, Arts-Cieslik K, et al. Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. Am J Roentgenol. 2006;186:1384-1392. (Pubitemid 46112577)
22. Durno CA, Sherman P, Williams T, et al. Magnetic resonance imaging to distinguish the type and severity of pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2000;30:170-174. (Pubitemid 30366194)
23. Punwani S, Rodriguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology. 2009.
24. Horsthuis K, Bipat S, Stokkers PC, et al. Magnetic resonance imaging for evaluation of disease activity in Crohn's disease: a systematic review. Eur Radiol. 2009.
25. Misselwitz B, Platzek J, Raduchel B, et al. Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography. Magma. 1999;8:190-195. (Pubitemid 29436572)
26. Meding J, Urich M, Licha K, et al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast Media Mol Imaging. 2007;2:120-129. (Pubitemid 47180344)
27. Belmiro CL, Souza HS, Elia CC, et al. Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease. Int J Colorectal Dis. 2005;20:295-304. (Pubitemid 40909225)
28. Barkhausen J, Ebert W, Heyer C, et al. Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging. Circulation. 2003; 108:605-609. (Pubitemid 36961177)
29. Misselwitz B, Platzek J, Weinmann HJ. Early MR lymphography with gadofluorine M in rabbits. Radiology. 2004;231:682-688. (Pubitemid 38668083)
30. Goldstein NS, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol. 1999;111:349-351. (Pubitemid 29102743)
31. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:21-33.
32. Plevy S. The immunology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:77-92. (Pubitemid 34733034)
33. Leon F, Smythies LE, Smith PD, et al. Involvement of dendritic cells in the pathogenesis of inflammatory bowel disease. Adv Exp Med Biol. 2006;579: 117-132.
34. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. (Pubitemid 34851835)
35. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. (Pubitemid 47123518)
36. Murch SH, MacDonald TT, Walker-Smith JA, et al. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet. 1993;341:711-714. (Pubitemid 23085176)
37. Frericks BB, Wacker F, Loddenkemper C, et al. Magnetic resonance imaging of experimental inflammatory bowel disease: quantitative and qualitative analyses with histopathologic correlation in a rat model using the ultrasmall iron oxide SHU 555 C. Invest Radiol. 2009;44:23-30.
38. Henning TD, Saborowski O, Golovko D, et al. Cell labeling with the positive MR contrast agent gadofluorine M. Eur Radiol. 2007;17:1226-1234. (Pubitemid 46691952)
39. Zheng J, Ochoa E, Misselwitz B, et al. Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Invest Radiol. 2008;43:49-55.
40. Fredin MF, Hultin L, Hyberg G, et al. Predicting and monitoring colitis development in mice by micro-computed tomography. Inflamm Bowel Dis. 2007.
41. Chung JJ, Semelka RC, Martin DR, et al. Colon diseases: MR evaluation using combined T2-weighted single-shot echo train spin-echo and gadolinium-enhanced spoiled gradient-echo sequences. J Magn Reson Imaging. 2000;12:297-305. (Pubitemid 30612874)
42. Rottgen R, Grandke T, Grieser C, et al. Measurement of MRI enhancement kinetics for evaluation of inflammatory activity in Crohn's disease. Clin Imaging. 2010;34:29-35.